Leo Pharma to terminate up to 150 R&D jobs

10–15 percent of positions in Leo Pharma’s research and development unit will be trimmed as a consequence of the announced restructuring of the company. A new strategy is to motivate the remaining R&D team, says the company’s head of global research and development.

Leo Pharma is closing down around 10–15 percent of positions in its R&D unit | Photo: Leo Pharma/PR

Dermatology firm Leo Pharma is closing between 100 and 150 jobs in its research and development unit, which currently counts around 1,000 employees.

”We want to focus on the R&D organization,” says Jörg Möller, head of global research and development at Leo Pharma, to MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs